Email Updates

You are here

Home»Media

AVAC in the News

  • FDA Approves First Long-Acting Injectable to Prevent HIV Infection

    The first long-acting injectable for HIV prevention has now been approved for use, the FDA announced on Monday. Long-acting injectable cabotegravir (CAB-LA, branded as Apretude) is administered as a monthly injection for the first 2 months, then every 2 months afterwards. It is the first long-acting injectable for pre-exposure prophylaxis (PrEP). The drug is approved for adults and adolescents weighing at least 77 lb.

    December 22, 2021
    PrEP
    MedPage Today

  • Although PrEP is Largely Underutilized, Developing Strategies Aim to Increase Initiation

    There had been more 200,000 pre-exposure prophylaxis (PrEP) initiations in North America from 2016-2020, according to data from the AVAC earlier this year. While the US is highly contributory to the gradually increasing rate of HIV-risk persons gaining access to PrEP annually, it’s not enough to consider the work accomplished on a national scale.

    December 22, 2021
    PrEP
    Contagion Live

  • Strategies Are Developing to Boost HIV PrEP Initiation

    There had been more 200,000 pre-exposure prophylaxis (PrEP) initiations in North America from 2016-2020, according to data from AVAC earlier this year. While the US is highly contributory to the gradually increasing rate of HIV-risk persons gaining access to PrEP annually, it’s not enough to consider the work accomplished on a national scale.

    December 15, 2021
    PrEP
    HCP Live

  • How HIV Research Paved the Way for the COVID mRNA Vaccines

    Every Dec. 1, the world commemorates those who have died from an AIDS-related illness. Known as World AIDS Day, it serves as a reminder that there has been an ongoing pandemic for the past 40 years, pre-dating COVID. The COVID vaccines were sequenced, developed and approved in the US in record time, but that would not have been possible without decades of work by HIV researchers.

    December 1, 2021
    HIV Vaccine
    CNBC

  • The Current

    The COVID-19 pandemic has complicated — and in some cases halted — the fight against HIV/AIDS. We talk about that impact with Hombisa Ntsikanye, an implementer and developer of the HIV and AIDS program at Blue Roof Life Space in Durban, South Africa; and Mitchell Warren, executive director of the AIDS Vaccine Advocacy Coalition.

    December 1, 2021
    General
    CBC

  • COVID Has Hurt the Fight Against AIDS, Experts Say — But It Could Also Lead to an HIV Vaccine

    Dr. Anthony Fauci, the top US infectious disease expert, said Tuesday the COVID-19 pandemic has diverted scientific and financial resources from the fight against AIDS, seriously impeding global efforts to achieve the UN goal of ending AIDS by 2030.

    December 1, 2021
    HIV Vaccine
    NBC News

  • An HIV-Prevention Drug Is Widely Available. Yet At-Risk Women Are Getting Left Behind

    In the US, women account for a fifth of new infections. But a persistent lack of education means few even know about the highly effective medication known as PrEP.

    December 1, 2021
    PrEP
    National Geographic

  • Shifts in UNAIDS Ethics Guidance and Implications for Ethics Review of Preventive HIV Vaccine Trials

    There have been several shifts in the UNAIDS ethics guidance with implications for HIV vaccine researchers submitting applications for initial ethics review or re-certification, and for RECs conducting such reviews. This review may assist RECs in a more efficient and consistent application of ethics recommendations. However, additional tools and training may further help stakeholders comply with new UNAIDS ethics recommendations during protocol development and ethics review.

    November 21, 2021
    HIV Vaccine
    JIAS

  • HIV Prevention Today: Do We Still Need a Vaccine? A Community Perspective

    Despite tremendous advances made in the global HIV response, overall progress in HIV prevention efforts remains too slow to reach the 2030 targets. In 2019 alone, 1.7 million people acquired HIV, three times more than the UNAIDS 2020 target. About 62 percent of the new infections were among key populations, these are men who have sex with men, sex workers, transgender people and people who inject drugs, and their sexual partners, and one in four new infections in sub-Saharan Africa are among adolescent girls and young women.

    November 21, 2021
    HIV Vaccine
    JIAS

  • To Save Lives, Confirm Dr. John Nkengasong to Head PEPFAR by World AIDS Day

    We were among the many advocates and global health leaders who called on the Biden Administration to move quickly in naming a permanent head for the US President’s Emergency Plan for AIDS Relief. Now that President Biden has selected Dr. John Nkengasong as his nominee, Congress must act swiftly to confirm his nomination and give US global efforts to address HIV – a preventable and treatable disease that still claims nearly 700,000 lives a year around the world, four decades after the first case was discovered – the permanent leadership it needs and deserves.

    October 29, 2021
    General
    Science Speaks

Pages